Rebif and Color blindness - a phase IV clinical study of FDA data


Color blindness is reported only by a few people who take Rebif.

The phase IV clinical study analyzes which people take Rebif and have Color blindness. It is created by eHealthMe based on reports of 58,459 people who have side effects while taking Rebif from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Aug, 17, 2022

58,459 people reported to have side effects when taking Rebif.
Among them, 5 people (0.01%) have Color blindness.

What is Rebif?

Rebif has active ingredients of interferon beta-1a. It is often used in multiple sclerosis. eHealthMe is studying from 56,560 Rebif users for its effectiveness, alternative drugs and more.

What is Color blindness?

Color blindness (inability to view some colour) is found to be associated with 469 drugs and 335 conditions by eHealthMe.

Number of Rebif and Color blindness reports submitted per year:

Could Rebif cause Color blindness?

Time on Rebif when people have Color blindness *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 100 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Color blindness when taking Rebif *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Color blindness when taking Rebif *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 20 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 80 %
  • 50-59: 0.0 %
  • 60+: 0.0 %

Common drugs people take besides Rebif *:

  1. Rabeprazole Sodium: 4 people, 80.00%
  2. Gabapentin: 4 people, 80.00%
  3. Clonazepam: 4 people, 80.00%
  4. Advil: 3 people, 60.00%
  5. Motrin: 1 person, 20.00%
  6. Advil Liqui-Gels: 1 person, 20.00%

Common side effects people have besides Color blindness *:

  1. Vision Blurred: 5 people, 100.00%
  2. Vitreous Floaters (spots before the eyes): 4 people, 80.00%
  3. Pain In Extremity: 4 people, 80.00%
  4. Joint Pain: 4 people, 80.00%
  5. Influenza Like Illness: 4 people, 80.00%
  6. Hypoaesthesia (reduced sense of touch or sensation): 4 people, 80.00%
  7. Diarrhea: 4 people, 80.00%
  8. Constipation: 4 people, 80.00%
  9. Balance Disorder: 4 people, 80.00%
  10. Photopsia (presence of perceived flashes of light): 3 people, 60.00%

* Approximation only. Some reports may have incomplete information.

Do you take Rebif and have Color blindness?

Check whether Color blindness is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Color blindness and when was it recovered:

Expand to all the drugs that have ingredients of interferon beta-1a:

Alternative drugs to, pros and cons of Rebif:

Common Rebif side effects:

Browse all side effects of Rebif:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Color blindness treatments and more:

COVID vaccines that are related to Color blindness:

All the drugs that are associated with Color blindness:

Common conditions associated with Color blindness:

All the conditions that are associated with Color blindness:

How the study uses the data?

The study uses data from the FDA. It is based on interferon beta-1a (the active ingredients of Rebif) and Rebif (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: